1Khan F, Shukla I, Rivzi M. The role of non-13-1actam antimierobials and screening for vancomycin resistance in methicillin resistant Staphy- lococcus aureus[ J ]. Malaysian Journal of Microbiology,2011,7(2) :66- 7O.
2Grammatikos AP,Falagas ME. Linezolid for the treatment of skin and soft-tissue infections [ J ]. Expert Rev. Dermato1,2008,3 (5) :539-548.
3Poulakou G,Giamarellou H. Investigational treatments for postoperative surgical site infections [ J ]. Expert Opin Investing Drugs, 2007, 16 (2) : 137-155.
5Falagasm E, Kastoris AC, Kapaskelis AM. Fosfomyein for the treat- ment of multidrug-resistant, including extended-spectrum beta-lacta- mase producing, Enter obaeteriaceae infections : a systematic review [J]. Lancet Infect Dis, 2010, 10 (1) : 43-50.
6Stein GE, Schooley S, Peloquin CA, et al. Linezolid tissue penetration andsemm activity against strains of methicillinresistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patientswith foot infections [ J ]. J Antimicrob Chemother,2007 ,60 : 819-823.
7Ohlsen K. Novel antibiotics for the treatment of Staphylococcus aureus. [J]. Expert Rev Clin Pharmacol ,2009 ,2 ( 6 ) :661-672.
9Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or 15-1actam for treatment of Gram-positive bacterial infections:meta-anal- ysis of randomised controlled trials[J]. Lancet Infect Dis ,2008,8( 1 ) : 53-66.
10Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/ pharmacodynamic profile in critically ill septic patients:intermittent versus continuous infusion [ J ]. Int J Antimicrob Agents,2008,31 (2) : 122-129.
8DIEKENA DI, JONES RN. Oxazolidinones: a review [ J ]. Drugs, 2000,59( 1 ) :7 - 16.
9MOELLERING RC JR. Linezolid:the first oxazolidinone antimicrobial[ J], Ann Intern Med,2003,138(2) :135 - 142.
10MEAGHER AK, FORREST A, RAYNER CA, et al. Population pharmacoklnetics of linezalid in patients treated in a compassionate-use program [ J ]. Antimicrob Agents Chemother, 2003,47 ( 2 ) : 548 - 553.
2Theuretzbacher U, Mouton J W. Update on antibacterial and antifungal drugs can we master the resistance crisis ? [J]. Curr Opin Pharmacol, 2011, 11 (5): 429-432.
3Auckland C, Teare L, Cooke F, et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom [J]. J Antimicrob Chemother, 2002, 50 (5): 743-746.
4Srivastava B K, Soni R, Jayendra Z, et al. Oxazolidinone antibacterialsand our experience [J]. Anti-Infect Agents Med Chem, 2008, 7 (4): 258- 280.
5Barbachyn M R, Ford C W. relationships leading to linezolid Oxazolidinone structure-activity [J]. Angew Chem lnt Ed, 2003, 42 (18):2010-2023.
6Pandit N, Singla R K, Shrivastava B. Current updates on oxazolidinone and its significance [J]. lnt J Med Chem, 2012, 2012:1-24.
7Komine T, Kojima A, Asahina Y, et al. Synthesis and structure-activity relationship studies of highly potent novel oxazolidinone antibacterials[J]. J Med Chem, 2008, 51: 6558-6562.
8Prasad V. New oxazolidinones [J]. Curr Opin Microbiol, 2007, 10: 454- 460.
9Michalska K, Karpiuk I, Kr61 M. Recent development of potent analogues of oxazolidinone antibacterial agents [J]. Bioogan Med Chem, 2013, 21(3): 577-591.
10D'Andrea S, Zheng Z B, Denbleyker K, et al. Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid [J]. Bioorg Med Chem Lett, 2005, 15 (11): 2834- 2839.
